Intestinal Pseudo-obstruction Treatment Market Trends

  • Report ID: 5760
  • Published Date: Nov 27, 2024
  • Report Format: PDF, PPT

Intestinal Pseudo-obstruction Treatment Market Trends

Growth Drivers

  • Impact of the Sedentary Lifestyle   - Sedentary behavior signifies less movement, so fewer calories are scorched. It’s suggested that adults and teens perform at least 2.5 hours of physical activity weekly to limit the opportunity for heart disease. However current studies demonstrate that only one in five people have the exercise they should – this can outcome in unplanned weight gain and possibly obesity. Of the many positive transformations that have happened in their production during the 21st century, one of the adverse prospects has been the kind of appearing and rising trend of a sedentary lifestyle. Related to their grandparents or parents, there is a substantial reduction in physical activity and a rise in health complexities. The indications of a sedentary lifestyle can be both physical and mental, and sometimes they’re so small that it may not even acknowledge they’re emerging. It’s significant to comprehend and recognize the indications so they can make changes to modify your health and quality of life.
  • Advancements in Diagnostic Equipment - A massively low incidence, non-particular clinical symptoms, powerful heterogeneity, and no definitive cause in some patients make CIPO very difficult to diagnose correctly. Imaging and gastrointestinal manometry are usually utilized. Most patients have advanced worsening of their symptoms and require arbitration, and nutritional assessment and treatment are very important to determine the prognosis. With modifications in surgical processes, small bowel transplantation is a possible therapy choice for patients with advanced CIPO; but, the permanent prognosis for CIPO patients stays unsatisfactory. Usually, the disease is rare and tough to diagnose, which leads to clinicians’ shortage of comprehension of the disease and outcomes in a high rate of misdiagnosis. This review explains the features of CIPO and the new developments in diagnosis and therapy, in detail. The objective of their review is to modify clinicians' comprehension of CIPO so that the disease is recognized promptly and precisely, and cured as early as feasible to modify patients’ quality of life.
  • Increasing Emphasis on Patient-Centric Care - Patients are living longer with chronic situations because of these progresses, and their role in health care is transforming from that of an inactive recipient of medical care to an active participant in clinical decision-making. These reasons are now putting the burden on the intricate, expensive, and frequently fragmented U.S. healthcare system to modify quality, as deliberated by patient experience.

Challenges

  • High Cost of Treatment of Intestinal Pseudo-obstruction - Acute colonic pseudo-obstruction is the clinical syndrome of sharp large bowel dilatation without mechanical impediment that is a significant cause of unwholesomeness and mortality. Intense colonic pseudo-obstruction takes place in hospitalized or institutionalized patients with severe fundamental medical and surgical situations. The pathogenesis of sharp colonic pseudo-obstruction is not realized but possibly results from inequality in the autonomic control of colonic motor function. Metabolic or pharmacological reasons, along with spinal or para-peritoneal trauma, may convert the autonomic rules of colonic operation, taking to unreasonable parasympathetic repression or sympathetic excitement. This disparity results in colonic atony and distension. Prior acknowledgment and suitable maintenance are crucial to limiting unwholesome and death. The mortality rate is projected at 40% when ischemia or puncture appears. The best-studied therapy of sharp colonic pseudo-obstruction is hypodermic neostigmine, which takes prompt colon decompression in the abundance of patients after a single infusion.
  • Side Effects Related to the Medications
  • Lack of Knowledge in People

Intestinal Pseudo-obstruction Treatment Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

5.1%

Base Year Market Size (2024)

USD 24.33 billion

Forecast Year Market Size (2037)

USD 46.45 billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5760
  • Published Date: Nov 27, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of intestinal pseudo-obstruction treatment is evaluated at USD 25.32 billion.

The intestinal pseudo-obstruction treatment market size was valued at USD 24.33 billion in 2024 and is set to exceed USD 46.45 billion by 2037, expanding at over 5.1% CAGR during the forecast period i.e., between 2025-2037. The increased frequency of gastrointestinal disease will drive the market growth.

North America industry is anticipated to account for largest revenue share of 45% by 2037, owing to increasing advancement in the tools of diagnosis in this region.

The major players in the market are GlaxoSmithKline Plc., Abbott Laboratories, Pfizer Inc., Johnson & Johnson, Callisto Pharmaceuticals Inc., Biogen Inc., Novartis A.G., Canila Healthcare Ltd, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Co Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample